Evidence map›Paper›PMID 41006293›Full record

ArticleScientific reports2025

Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics.

Amer H Tarawneh, Salah A Al-Trawneh, Talha Z Yesiloglu, Matthes Zessin, Dina Robaa, Cyril Barinka, Mike Schutkowski, Wolfgang Sippl, Samir A Ross

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amer H TarawnehDepartment of Chemistry, Faculty of Science, Tafila Technical University, P.O. Box 179, Tafila, 66110, Jordan. amer.tarawneh@ttu.edu.jo.
Salah A Al-TrawnehChemistry Department, Faculty of Science, Mu'tah University, Karak, 61710, Jordan. laratr@mutah.edu.jo.
Talha Z YesilogluInstitute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120, Halle/Saale, Germany.
Matthes ZessinInstitute of Biotechnology, Martin-Luther University of Halle-Wittenberg, 06120, Halle/Saale, Germany.
Dina RobaaInstitute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120, Halle/Saale, Germany.
Cyril BarinkaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50, Vestec, Czech Republic.
Mike SchutkowskiInstitute of Biotechnology, Martin-Luther University of Halle-Wittenberg, 06120, Halle/Saale, Germany.
Wolfgang SipplInstitute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120, Halle/Saale, Germany. wolfgang.sippl@pharmazie.uni-halle.de.
Samir A RossNational Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, 38677, USA. sross@olemiss.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that play a key role in both epigenetic and non-epigenetic regulation, leading to cancer cell death, apoptosis, and cell cycle arrest. This study synthesized novel bicyclic hydroxamic acid derivatives and evaluated their inhibitory and selectivity activity against class I and IIb HDACs. Our findings demonstrate that Compound 2e specifically inhibits HDAC10 with high selectivity over HDAC6, while shows no significant impact on class I HDACs. Compound 2a exhibited the most potant inhibitory activity against HDAC10, with IC

Indexed as

Antineoplastic AgentsHistone Deacetylase InhibitorsHistone DeacetylasesIndolesAnimalsCatalytic DomainCell Line, TumorCell ProliferationHumansMolecular Docking SimulationMolecular Dynamics SimulationAntineoplastic AgentsHDAC10 protein, humanHistone Deacetylase InhibitorsHistone DeacetylasesIndolesHDAC10 inhibitorsHistone deacetylasesMolecular dockingMolecular dynamicsTumor cell lines

Identifiers

PMID41006293
PMCPMC12475083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.